TKT and non-small cell lung carcinoma: Less than 18 months ago, it was found that activating mutations in the TK domain of the gene occurred in a subset of non-small-cell lung cancer (NSCLC), especially adenocarcinomas, and predicted, though not precisely, the response to small molecule inhibitors [4–6].